drugset / Trial / NCT03465787
A 6-week Study to Evaluate the Efficacy and Safety of Lurasidone HCL in Acutely Psychotic Patients With Schizophrenia
RandomizedParallel-groupDouble-blindTreatment
Summary
This is a study designed to evaluate the efficacy and safety of lurasidone in acutely psychotic patients with chronic schizophrenia and to confirm the non-inferiority of lurasidone relative to quetiapine XR.
Timeline
- Start
- 2018-04-09
- Primary completion
- 2022-10-26
- Completion
- 2022-10-26
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lurasidone | Small molecule | 160 mg | — |
| Comparator | Quetiapine | Small molecule | 600 mg | — |